Monthly Archives: July 2019

Fed. Cir. affirms obviousness of Celgene’s claims and finds IPRs against pre-AIA patents not unconstitutional

Posted on July 31, 2019 by Patrick J. Halloran, Ph.D., J.D.

Celgene Corp. v. Laura A. Peter (USPTO) Docket No. 2018-1167, -1168, -1169, -1171 (IPR2015-01096, -01102, -01103, -01092) TARANTO, MAYER, CHEN July 30, 2019 Brief Summary: Board obviousness determinations of Celgene’s thalidomide administration-related claims affirmed; arguments that IPRs are unconstitutional for … Continue reading →

Posted in Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Ford’s hood and headlamp design patents valid design subject matter and not exhausted by sale of Ford F-150 truck

Posted on July 25, 2019 by Patrick J. Halloran, Ph.D., J.D.

Automotive Body Parts Association v. Ford Global Technologies, LLC Docket No. 2018-1613 Hughes, Scholl, Stoll July 23, 2019 Brief Summary: DC decision that Ford’s hood and headlamp design patents are not “primarily functional” designs and not unenforceable under doctrines of … Continue reading →

Posted in Design Patents, Exhaustion and Repair, Uncategorized | Leave a comment

Board IPR claim construction “in the context of this patent” and anticipation/obviousness determinations affirmed

Posted on July 23, 2019 by Patrick J. Halloran, Ph.D., J.D.

CCS Technology, Inc. v. Panduit Corp. Docket No. 2018-1733, -1734 (IPR2016-01647, -01648) TARANTO, MAYER, CHEN July 19, 2019 Non-precedential Brief Summary: Board’s IPR claim construction (broadest reasonable construction) and findings of invalidity for anticipation and obviousness affirmed. Summary: CCS appealed … Continue reading →

Posted in Anticipation (35 USC 102), Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Board IPR obviousness finding affirmed, TQ Delta had “opportunity to be heard”

Posted on July 22, 2019 by Patrick J. Halloran, Ph.D., J.D.

TQ Delta, LLC v. Dish Network LLC Docket No. 2018-1799 (IPR2016-01470) NEWMAN, LINN, WALLACH July 10, 2019 Brief Summary: Board IPR FWD finding TQ Delta’s communications systems claims obvious affirmed. Summary: TQ Delta appealed Board IPR Final Written Decision (FWD) … Continue reading →

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away, Uncategorized | Leave a comment

GE’s “purported competitive injuries” found not to provide standing to appeal IPR

Posted on July 18, 2019 by Patrick J. Halloran, Ph.D., J.D.

General Electric Company (GE) v. United Technologies Corporation (UTC) Docket No. 2017-2497 (IPR2016-00531) REYNA, TARANTO, HUGHES July 10, 2019 Brief Summary: GE appealed Board IPR finding claims 7-11 of UTC’s US 8,511,605 relating to gear fan gas turbine engines not … Continue reading →

Posted in Appeal, Inter Parties Review (IPR), IPR | Leave a comment

Federal Circuit vacates and remands IPR decisions based on public accessibility

Posted on July 16, 2019 by Patrick J. Halloran, Ph.D., J.D.

Samsung Electronics Co., Ltd. v. Infobridge PTE. Ltd. Docket Nos. 2018-2007, -2012 (IPR2017-00099, -00100) Newman, Schall, O’Malley July 12, 2019 Brief Summary: Board IPR decisions based on no public accessibility vacated and remanded (e.g., “a petitioner need not establish that … Continue reading →

Posted in Anticipation (35 USC 102), Obviousness, Public Accessibility, Public Use | Leave a comment

DC decision that Invidior’s Suboxone® sublingual film patents are infringed by certain parties and not invalid for obviousness affirmed

Posted on July 15, 2019 by Patrick J. Halloran, Ph.D., J.D.

Invidior Inc. et al. v. Dr. Reddy’s Labs. (DRL), Actavis/Watson, Teva, Par, Intelgenx, Alvogen Pine Brook, LLC Docket Nos. 2017-2587, 2018-1010, -1058, -1062, -1114, -1115, -1176, -1177 Newman, Mayer (D), Lourie July 12, 2019 Brief Summary: DC findings that Invidior … Continue reading →

Posted in Claim Construction, Doctrine of equivalents, Generics / ANDA, Obviousness, Written description | Leave a comment

Federal Circuit affirms Board decision finding chromosomal abnormality testing claims lack written description affirmed

Posted on July 11, 2019 by Patrick J. Halloran, Ph.D., J.D.

Stephen Quake, et al. v. Yuk-Ming Dennis Lo, et al. Docket Nos. 2018-1779, -1780, -1782 Reyna, Chen, Hughes July 10, 2019 Brief Summary: Board finding of no WD of chromosomal abnormality testing claims affirmed. Summary: Quake appealed Board decision finding … Continue reading →

Posted in Interference, Written description | Leave a comment

Board written description decision vacated as conflicting with Ariad (predictability relevant to WD analysis)

Posted on July 10, 2019 by Patrick J. Halloran, Ph.D., J.D.

In re: Global IP Holdings, LLC Docket Nos. 2018-1426 Moore, Reyna, Stoll July 5, 2019 Brief Summary: Board decision affirming rejection of broadening reissue claims for lacking written description vacated and remanded (e.g., Board’s statement “that the ‘233 patent’s specification … Continue reading →

Posted in Reissue, Written description | Leave a comment

Federal Circuit affirms DC’s grant of SJ, finding Enzo’s claims invalid for lack of enablement

Posted on July 9, 2019 by Patrick J. Halloran, Ph.D., J.D.

Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc. et al. (Becton Dickinson (BD), GeneOhm, Aboott) Docket Nos. 2017-2498, -2499, -2545, -2546 (public opinion: July 25, 2019) Brief Summary:  DC grant of SJ for invalidity of Enzo’s claims for lack … Continue reading →

Posted in Enablement, Uncategorized | Leave a comment